Insider Trading Alert - SNAK, PCLN And RMD Traded By Insiders

Yesterday, March 16, 2016, 100 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $51.12 to $7,757,838.42.

Highlighted Stocks Traded by Insiders:

Inventure Foods (SNAK) - FREE Research Report

Weinberger Steve, who is Cfo at Inventure Foods, sold 9,936 shares at $5.72 on March 16, 2016. Following this transaction, the Cfo owned 136,146 shares meaning that the stake was reduced by 6.8% with the 9,936-share transaction.

The shares most recently traded at $5.67, down $0.05, or 0.91% since the insider transaction. Historical insider transactions for Inventure Foods go as follows:

  • 4-Week # shares bought: 5,000
  • 4-Week # shares sold: 6,407
  • 12-Week # shares bought: 5,000
  • 12-Week # shares sold: 6,407
  • 24-Week # shares bought: 5,000
  • 24-Week # shares sold: 6,407

The average volume for Inventure Foods has been 174,500 shares per day over the past 30 days. Inventure Foods has a market cap of $110.8 million and is part of the consumer goods sector and food & beverage industry. Shares are down 19.58% year-to-date as of the close of trading on Wednesday.

Inventure Foods, Inc. manufactures and markets healthy/natural and indulgent specialty snack food products in the United States and internationally. It operates in two segments, Frozen Products and Snack Products. Currently, there are 6 analysts who rate Inventure Foods a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on SNAK - FREE

TheStreet Quant Ratings rates Inventure Foods as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, generally high debt management risk, disappointing return on equity, poor profit margins and generally disappointing historical performance in the stock itself. Get the full Inventure Foods Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Priceline Group (PCLN) - FREE Research Report

Millones Peter J, who is Executive VP, General Counsel at Priceline Group, sold 5,871 shares at $1,321.38 on March 16, 2016. Following this transaction, the Executive VP, General Counsel owned 6,792 shares meaning that the stake was reduced by 46.36% with the 5,871-share transaction.

Tans Gillian, who is President & COO, Booking.com at Priceline Group, sold 130 shares at $1,315.15 on March 16, 2016. Following this transaction, the President & COO, Booking.com owned 2,949 shares meaning that the stake was reduced by 4.22% with the 130-share transaction.

The shares most recently traded at $1,346.78, up $31.63, or 2.35% since the insider transaction. Historical insider transactions for Priceline Group go as follows:

  • 4-Week # shares sold: 3,161
  • 12-Week # shares sold: 3,483
  • 24-Week # shares sold: 12,966

The average volume for Priceline Group has been 745,900 shares per day over the past 30 days. Priceline Group has a market cap of $66.1 billion and is part of the services sector and diversified services industry. Shares are up 5.96% year-to-date as of the close of trading on Wednesday.

The Priceline Group Inc. provides online travel and restaurant reservation and related services. The company has a P/E ratio of 26.9. Currently, there are 10 analysts who rate Priceline Group a buy, no analysts rate it a sell, and 7 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on PCLN - FREE

TheStreet Quant Ratings rates Priceline Group as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, expanding profit margins and solid stock price performance. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Priceline Group Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

ResMed (RMD) - FREE Research Report

Hollingshead James, who is President, Americas at ResMed, sold 4,500 shares at $58.57 on March 16, 2016. Following this transaction, the President, Americas owned 47,569 shares meaning that the stake was reduced by 8.64% with the 4,500-share transaction.

The shares most recently traded at $56.08, down $2.49, or 4.44% since the insider transaction. Historical insider transactions for ResMed go as follows:

  • 4-Week # shares sold: 31,946
  • 12-Week # shares sold: 31,946
  • 24-Week # shares sold: 61,888

The average volume for ResMed has been 1.2 million shares per day over the past 30 days. ResMed has a market cap of $8.2 billion and is part of the health care sector and health services industry. Shares are up 6.72% year-to-date as of the close of trading on Wednesday.

ResMed Inc. develops, manufactures, distributes, and markets medical equipment for the diagnosis, treatment, and management of respiratory disorders with a focus on sleep-disordered breathing (SDB). The stock currently has a dividend yield of 2.04%. The company has a P/E ratio of 23.7. Currently, there are 4 analysts who rate ResMed a buy, 1 analyst rates it a sell, and 4 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on RMD - FREE

TheStreet Quant Ratings rates ResMed as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, good cash flow from operations and expanding profit margins. We feel its strengths outweigh the fact that the company has had lackluster performance in the stock itself. Get the full ResMed Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

More from Markets

Stocks Trade Lower as Amazon Rises, Apple and P&G Slump

Stocks Trade Lower as Amazon Rises, Apple and P&G Slump

Soaring Nickel Prices Could Be Bad News for Electric Carmakers Like Tesla

Soaring Nickel Prices Could Be Bad News for Electric Carmakers Like Tesla

Video: The Road to S&P 500 2,800 Is 'Slow and Choppy'

Video: The Road to S&P 500 2,800 Is 'Slow and Choppy'

Let the Najarian Brothers Help You Generate Income With Options

Let the Najarian Brothers Help You Generate Income With Options

Oil Stocks Jump as Global Crude Oil Rally Gains Steam

Oil Stocks Jump as Global Crude Oil Rally Gains Steam